VivoSeq
Immunology

Autoimmune Disorders

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Autoimmune Disorders is an early-stage landscape with 0 programs across 1 company. The most active players are Cartesian Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cartesian Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Enrolling by invitation1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
Enrolling by invitation·SSpanish Foundation for Neurometrics Development·Phase 1·NCT06368726·180 enrolled
A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
Completed·MmAbxience Research S.L.·Phase 1·NCT06392074·141 enrolled
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Recruiting·CCartesian Therapeutics·Phase 1/2·NCT07089121·50 enrolled
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06434363·47 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)